

David L Nelson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3124051/publications.pdf>

Version: 2024-02-01

75
papers

14,800
citations

66234

42
h-index

91712

69
g-index

78
all docs

78
docs citations

78
times ranked

9012
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of a gene (FMR-1) containing a CCG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. <i>Cell</i> , 1991, 65, 905-914.	13.5	3,285
2	Variation of the CCG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. <i>Cell</i> , 1991, 67, 1047-1058.	13.5	2,007
3	Absence of expression of the FMR-1 gene in fragile X syndrome. <i>Cell</i> , 1991, 66, 817-822.	13.5	1,408
4	DNA methylation represses FMR-1 transcription in fragile X syndrome. <i>Human Molecular Genetics</i> , 1992, 1, 397-400.	1.4	674
5	Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. <i>Nature Neuroscience</i> , 2004, 7, 113-117.	7.1	571
6	Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. <i>Nature Genetics</i> , 2000, 26, 191-194.	9.4	505
7	Length of uninterrupted CCG repeats determines instability in the FMR1 gene. <i>Nature Genetics</i> , 1994, 8, 88-94.	9.4	468
8	The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. <i>Nature</i> , 1992, 358, 239-242.	13.7	467
9	X-linked situs abnormalities result from mutations in ZIC3. <i>Nature Genetics</i> , 1997, 17, 305-308.	9.4	406
10	Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. <i>Nature Genetics</i> , 1993, 3, 36-43.	9.4	358
11	RNA-Binding Proteins hnRNP A2/B1 and CUGBP1 Suppress Fragile X CCG Premutation Repeat-Induced Neurodegeneration in a Drosophila Model of FXTAS. <i>Neuron</i> , 2007, 55, 565-571.	3.8	309
12	Human and murine FMR-1: alternative splicing and translational initiation downstream of the CCG repeat. <i>Nature Genetics</i> , 1993, 4, 244-251.	9.4	247
13	Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG island. <i>Nature Genetics</i> , 1996, 13, 109-113.	9.4	238
14	High functioning fragile X males: Demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. <i>American Journal of Medical Genetics Part A</i> , 1994, 51, 298-308.	2.4	213
15	The Unstable Repeats—Three Evolving Faces of Neurological Disease. <i>Neuron</i> , 2013, 77, 825-843.	3.8	192
16	Isolation of a GCC repeat showing expansion in FRAXF, a fragile site distal to FRAXA and FRAXE. <i>Nature Genetics</i> , 1994, 8, 229-235.	9.4	175
17	Bmal1 and δ -Cell Clock Are Required for Adaptation to Circadian Disruption, and Their Loss of Function Leads to Oxidative Stress-Induced δ -Cell Failure in Mice. <i>Molecular and Cellular Biology</i> , 2013, 33, 2327-2338.	1.1	175
18	Fine structure of the human FMR1 gene. <i>Human Molecular Genetics</i> , 1993, 2, 1147-1153.	1.4	171

#	ARTICLE	IF	CITATIONS
19	A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations. <i>Human Molecular Genetics</i> , 2001, 10, 2171-2179.	1.4	165
20	Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome. <i>Nature Genetics</i> , 1995, 10, 483-485.	9.4	152
21	AGC interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. <i>Genetics in Medicine</i> , 2012, 14, 729-736.	1.1	152
22	Atypical Forms of Incontinentia Pigmenti in Male Individuals Result from Mutations of a Cytosine Tract in Exon 10 of NEMO (IKK- β). <i>American Journal of Human Genetics</i> , 2001, 68, 765-771.	2.6	141
23	Interruptions in the Triplet Repeats of SCA1 and FRAXA Reduce the Propensity and Complexity of Slipped Strand DNA (S-DNA) Formation. <i>Biochemistry</i> , 1998, 37, 2701-2708.	1.2	139
24	Duplication of a gene-rich cluster between 16p11.1 and Xq28: a novel pericentromeric-directed mechanism for paralogous genome evolution. <i>Human Molecular Genetics</i> , 1996, 5, 899-912.	1.4	136
25	High resolution methylation analysis of the FMR1 gene trinucleotide repeat region in fragile X syndrome. <i>Human Molecular Genetics</i> , 1993, 2, 1659-1665.	1.4	122
26	Fragile X-Related Proteins Regulate Mammalian Circadian Behavioral Rhythms. <i>American Journal of Human Genetics</i> , 2008, 83, 43-52.	2.6	109
27	Altered Hippocampal Synaptic Plasticity in the <i>Fmr1</i> Gene Family Knockout Mouse Models. <i>Journal of Neurophysiology</i> , 2009, 101, 2572-2580.	0.9	108
28	Exaggerated behavioral phenotypes in <i>Fmr1/Fxr2</i> double knockout mice reveal a functional genetic interaction between Fragile X-related proteins. <i>Human Molecular Genetics</i> , 2006, 15, 1984-1994.	1.4	105
29	Ectopic expression of CGG containing mRNA is neurotoxic in mammals. <i>Human Molecular Genetics</i> , 2009, 18, 2443-2451.	1.4	104
30	Cloning of human and bovine homologs of SNF2/SWI2: a global activator of transcription in yeast <i>S.cerevisiae</i> . <i>Nucleic Acids Research</i> , 1992, 20, 4649-4655.	6.5	100
31	The GABA _A receptor is an FMRP target with therapeutic potential in fragile X syndrome. <i>Cell Cycle</i> , 2015, 14, 2985-2995.	1.3	87
32	Characterization of a highly polymorphic dinucleotide repeat 150 KB proximal to the fragile X site. <i>American Journal of Medical Genetics Part A</i> , 1992, 43, 237-243.	2.4	82
33	Molecular and phenotypic variation in patients with severe Hunter syndrome. <i>Human Molecular Genetics</i> , 1997, 6, 479-486.	1.4	82
34	NEMO, NF κ B signaling and incontinentia pigmenti. <i>Current Opinion in Genetics and Development</i> , 2006, 16, 282-288.	1.5	81
35	NF κ B signaling and human disease. <i>Current Opinion in Genetics and Development</i> , 2001, 11, 300-306.	1.5	79
36	Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo. <i>Journal of Neuroscience</i> , 2016, 36, 7079-7094.	1.7	77

#	ARTICLE	IF	CITATIONS
37	Comparative Genomic Sequence Analysis of the FXR Gene Family: FMR1, FXR1, and FXR2. <i>Genomics</i> , 2001, 78, 169-177.	1.3	76
38	Robust amplification and ethidium-visible detection of the fragile X syndrome CGG repeat using Pfu polymerase. <i>American Journal of Medical Genetics Part A</i> , 1994, 51, 522-526.	2.4	72
39	The adipocyte clock controls brown adipogenesis via TGF- β /BMP signaling pathway. <i>Journal of Cell Science</i> , 2015, 128, 1835-47.	1.2	63
40	Mouse models of the fragile X premutation and fragile X-associated tremor/ataxia syndrome. <i>Journal of Neurodevelopmental Disorders</i> , 2014, 6, 25.	1.5	57
41	Deletion of Fmr1 from Forebrain Excitatory Neurons Triggers Abnormal Cellular, EEG, and Behavioral Phenotypes in the Auditory Cortex of a Mouse Model of Fragile X Syndrome. <i>Cerebral Cortex</i> , 2020, 30, 969-988.	1.6	55
42	Evolution of the cryptic FMR1 CGG repeat. <i>Nature Genetics</i> , 1995, 11, 301-308.	9.4	52
43	Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in <i>Drosophila</i> . <i>Human Molecular Genetics</i> , 2012, 21, 2068-2075.	1.4	42
44	Desmoplakin and Talin2 Are Novel mRNA Targets of Fragile X-Related Protein-1 in Cardiac Muscle. <i>Circulation Research</i> , 2011, 109, 262-271.	2.0	41
45	FXR1P Limits Long-Term Memory, Long-Lasting Synaptic Potentiation, and De Novo GluA2 Translation. <i>Cell Reports</i> , 2014, 9, 1402-1416.	2.9	40
46	Genetic variation and evolutionary stability of the FMR1 CGG repeat in six closed human populations. , 1996, 64, 220-225.		32
47	A Primate Genome Project Deserves High Priority. <i>Science</i> , 2000, 289, 1295b-1296.	6.0	31
48	GENETICS: The Critical Region in Trisomy 21. <i>Science</i> , 2004, 306, 619-621.	6.0	29
49	MBD5 haploinsufficiency is associated with sleep disturbance and disrupts circadian pathways common to Smith-Magenis and fragile X syndromes. <i>European Journal of Human Genetics</i> , 2015, 23, 781-789.	1.4	29
50	Correction of GSK3 β at young age prevents muscle pathology in mice with myotonic dystrophy type 1. <i>FASEB Journal</i> , 2018, 32, 2073-2085.	0.2	27
51	Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. <i>Nature Communications</i> , 2019, 10, 797.	5.8	24
52	Genomic Comparisons of Humans and Chimpanzees. <i>Annual Review of Anthropology</i> , 2007, 36, 191-209.	0.4	23
53	The Fragile X proteins Fmrp and Fxr2p cooperate to regulate glucose metabolism in mice. <i>Human Molecular Genetics</i> , 2015, 24, 2175-2184.	1.4	23
54	CGG repeats in RNA modulate expression of TDP-43 in mouse and fly models of fragile X tremor ataxia syndrome. <i>Human Molecular Genetics</i> , 2014, 23, 5906-5915.	1.4	21

#	ARTICLE	IF	CITATIONS
55	The nature and consequences of fragile X syndrome. <i>Mental Retardation and Developmental Disabilities Research Reviews</i> , 1995, 1, 238-244.	3.5	15
56	Reduced mRNA for G3BP in fragile X cells: Evidence of FMR1 gene regulation. , 1999, 84, 268-271.		15
57	Physical and Genetic Characterization Reveals a Pseudogene, an Evolutionary Junction, and Unstable Loci in Distal Xq28. <i>Genomics</i> , 2002, 79, 31-40.	1.3	13
58	Intragenic probe used for diagnostics in fragile X families. <i>American Journal of Medical Genetics Part A</i> , 1992, 43, 192-196.	2.4	11
59	Metabolic pathways modulate the neuronal toxicity associated with fragile X-associated tremor/ataxia syndrome. <i>Human Molecular Genetics</i> , 2019, 28, 980-991.	1.4	10
60	Intercepting IRE1 kinaseâ€FMRP signaling prevents atherosclerosis progression. <i>EMBO Molecular Medicine</i> , 2022, 14, e15344.	3.3	10
61	Functional consequences of postnatal interventions in a mouse model of Fragile X syndrome. <i>Neurobiology of Disease</i> , 2022, 162, 105577.	2.1	9
62	Identification of <i>PSMB5</i> as a genetic modifier of fragile X-associated tremor/ataxia syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
63	Filamin (FLN1), plexin (SEX), major palmitoylated protein p55 (MPP1), and von-Hippel Lindau binding protein (VBP1) are not involved in incontinentia pigmenti type 2. <i>American Journal of Medical Genetics Part A</i> , 2000, 94, 79-84.	2.4	5
64	Intellectual and developmental disabilities research centers: Fifty years of scientific accomplishments. <i>Annals of Neurology</i> , 2019, 86, 332-343.	2.8	5
65	ASHG Perspectives: A New Voice for ASHG. <i>American Journal of Human Genetics</i> , 2018, 103, 635.	2.6	4
66	Ectopic expression of CCG-repeats alters ovarian response to gonadotropins and leads to infertility in a murine <i>FMR1</i> premutation model. <i>Human Molecular Genetics</i> , 2021, 30, 923-938.	1.4	4
67	Human homologue of the murine <i>bare patches/striated</i> gene is not mutated in incontinentia pigmenti type 2. , 2000, 91, 241-244.		3
68	Simultaneous Screening of the FRAXA and FRAXE Loci for Rapid Detection of FMR1 CCG and/or AFF2 CCG Repeat Expansions by Triplet-Primed PCR. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 941-951.	1.2	3
69	Stephen T. Warren, Ph.D. (1953â€2021): A remembrance. <i>American Journal of Human Genetics</i> , 2022, 109, 3-11.	2.6	2
70	Turning the corner from observation to intervention in human genetics. <i>Journal of Genetics and Genomics</i> , 2018, 45, 57-59.	1.7	1
71	2018 Presidential Address: Who Are We?. <i>American Journal of Human Genetics</i> , 2019, 104, 363-372.	2.6	1
72	2016 William Allan Award Introduction: James Gusella 1. <i>American Journal of Human Genetics</i> , 2017, 100, 385-386.	2.6	0

#	ARTICLE	IF	CITATIONS
73	Stephen T. Warren 1953–2021. <i>Nature Genetics</i> , 2021, 53, 1117-1118.	9.4	0
74	Stephen T. Warren: Human geneticist who advanced understanding of mutational mechanisms and developmental disorders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2112969118.	3.3	0
75	Positive Selection of a Pre-expansion CAG Repeat of the Human SCA2 Gene. <i>PLoS Genetics</i> , 2005, preprint, e41.	1.5	0